Boehringer Ingelheim awards its first Translational Medicine Award

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

  • The award recognizes the research with the highest translational potential
  • Translational medicine is an interdisciplinary branch in the biomedical field that aims to combine benchside, bedside and community to improve prevention, diagnosis and treatment

Ingelheim, Germany, October 11, 2021 Boehringer Ingelheim, a global leader in animal health, presented its first biennial Translational Medicine Award during the North American Veterinary Regenerative Medicine Association (NAVRMA 2021) conference in Colorado, USA, held at the Wayne McIlwraith Translational Medicine Institute at Colorado State University. The award recognizes the research presentation with the highest translational potential by identifying six potential award-winning candidates based on evaluation criteria based on abstract and title and selecting a winner based on the presentation and answers to the questions.

The general theme of the conference was “Cooperation”. With this award, Boehringer Ingelheim aims to demonstrate the company’s support and recognition for new ideas, passion and determination to bring the next wave of innovation to the animal health sector.

The winning research will receive $ 5,000 and a bronze horse for research with the highest translational potential; the investigator gets $ 1,000 and the research lab gets $ 4,000 to continue the great work.

That year, Prof. Boaz Arzi of the University of California, Davis, won the company’s first Translational Medicine Award. His presentation focused on the benefits of treating cats with chronic gingivostomatitis with cellular regenerative therapies.

“We are very excited about the innovative efforts of those who submitted their research for the award,” said Jan Spaas, General Manager Boehringer Ingelheim Veterinary Medicine Belgium. “The presentations were judged for their innovative character and their ability to become game changers in the field of veterinary regeneration. In addition to clinical safety and effectiveness, the research was judged on the basis of the product strength and the development phase for the end product. Other important aspects in the assessment were the market potential and the ability to offer animal patients added value. “

The jury consisted of the following professors and scientists: Tracy Webb and Wayne McIlwraith from Colorado State University and Sylvester Price and Jan Spaas from Boehringer Ingelheim.

Congratulations to the winner!

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, so are people. Our 9,700 employees worldwide are committed to creating value through innovation and thus increasing the well-being of both.

The focus of our actions is on respect for animals, people and the environment. We develop solutions and offer services to protect animals from disease and pain. We support our customers in caring for the health of their animals and protect our communities from life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health company in the world with net sales of 4.1 billion euros in 2020 and a presence in more than 150 countries. You can find more information at

Boehringer Ingelheim

Boehringer Ingelheim works on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned since then, Boehringer Ingelheim pursues a long-term perspective. Around 52,000 employees serve more than 130 stores in the three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. Find out more at